RARE

#1581
Ultragenyx Pharmaceutical Inc. - Common Stock
23.9 4 USD
+2.92%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
23.94
23.94
Range Annuel
18.29
42.37
Changement quotidien
+2.92%
Changement Mensuel
-2.17%
Evolution sur 6 mois
-29.98%
Changement Annuel
-31.34%
Clôture Précédente
23.2 6
Open
23.9 4
Low
23.9 4
High
23.9 4
Volume
142
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.

Nouvelles